Semaglutide vs Tirzepatide
Published Jul 4, 2026 · 4 minute read
Semaglutide and tirzepatide are the two molecules behind nearly every famous GLP-1 brand. Unlike Ozempic vs Wegovy or Mounjaro vs Zepbound, this is not the same drug under two names. These are genuinely different molecules, and the difference comes down to one extra receptor.
Key Takeaways
- Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist.
- Semaglutide is the molecule in Ozempic, Wegovy, and Rybelsus; tirzepatide is the molecule in Mounjaro and Zepbound.
- In separate pivotal obesity trials, the highest-dose tirzepatide arm showed larger mean weight loss than the highest-dose semaglutide arm.
- These are different trials, not a head-to-head comparison, so cross-trial numbers should be read with caution.
- Both are once-weekly injections made by different companies (Novo Nordisk and Eli Lilly).
- This page is educational and is not medical advice.
1. The Core Difference: One Receptor vs Two
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist: it activates both the GIP and GLP-1 receptors with one molecule. That second receptor target is the defining distinction.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptors targeted | GLP-1 | GIP + GLP-1 |
| Maker | Novo Nordisk | Eli Lilly |
| Diabetes brand | Ozempic, Rybelsus | Mounjaro |
| Weight-management brand | Wegovy | Zepbound |
| Injectable schedule | Once weekly | Once weekly |
For the receptor-count framing, see GLP-1 vs GLP-2 vs GLP-3.
2. What the Pivotal Trials Showed
Each molecule has a landmark Phase 3 obesity trial. Semaglutide’s is STEP 1; tirzepatide’s is SURMOUNT-1.
3. Read Cross-Trial Numbers With Care
It is tempting to line up 14.9% against 20.9% and call it settled. But STEP 1 and SURMOUNT-1 were separate trials, with different participants, sites, and time frames. They were not a direct head-to-head, so the gap is indicative rather than definitive, and individual outcomes vary widely.
4. The Brand Families at a Glance
Because each molecule has multiple brands, the names multiply quickly. Here is the full map.
| Molecule | Class | Diabetes | Weight management | Oral |
|---|---|---|---|---|
| Semaglutide | GLP-1 | Ozempic | Wegovy | Rybelsus, Wegovy pill |
| Tirzepatide | GIP/GLP-1 | Mounjaro | Zepbound | None currently |
For a brand-level breakdown, see Ozempic vs Mounjaro.
5. What Comes After Two Receptors
If one receptor is semaglutide and two is tirzepatide, the natural next step is three. The investigational triple agonist retatrutide adds glucagon receptor activity on top of GIP and GLP-1, and several other dual and triple agonists are in development.
6. Tracking Either Molecule
For personal records, the molecule and brand both matter: log which product, the dose, timing, and injection site consistently. See the semaglutide tracking guide and tirzepatide tracking guide.
7. Semaglutide vs Tirzepatide FAQ
What is the main difference between semaglutide and tirzepatide?
Semaglutide activates one receptor, GLP-1. Tirzepatide activates two, GIP and GLP-1. That extra receptor target is the headline mechanistic difference, and tirzepatide trials have generally reported larger average weight loss.
Which causes more weight loss, semaglutide or tirzepatide?
In separate Phase 3 obesity trials, the highest tirzepatide dose (SURMOUNT-1, about 20.9%) showed greater mean weight loss than the highest semaglutide dose (STEP 1, about 14.9%). Because these are different trials with different populations, the comparison is indicative, not a direct head-to-head, and individual results vary. This is not medical advice.
Are semaglutide and tirzepatide the same drug class?
They overlap but are not identical. Both act on the GLP-1 receptor, but tirzepatide adds GIP receptor activity, so FDA labeling describes tirzepatide as a GIP/GLP-1 receptor agonist rather than a GLP-1 agonist.
What brands contain semaglutide and tirzepatide?
Semaglutide is sold as Ozempic and Rybelsus (diabetes) and Wegovy (weight management). Tirzepatide is sold as Mounjaro (diabetes) and Zepbound (weight management and obstructive sleep apnea).
Are they both once-weekly injections?
The injectable forms of both are once weekly. Semaglutide also has oral tablet forms (Rybelsus and an oral Wegovy pill); tirzepatide is currently injectable.